Related Experiment Videos
Abstract:
Fosfomycin was exclusively used as antibiotic treatment in 37 patients suffering from osteomyelitis, out ot which 23 were operated for sequestrectomy or fistulectomy, whereas the remaining 14 did not undergo any surgery during fosfomycin treatment. Fosfomycin was adminsitered parenterally, alone or combined with oral administration, and in some cases only orally. The dosage varied from 4 to 8 g/day for an average period of 3 weeks. After one or two treatments the results were 29 definitive cures (78%), 2 failures and 6 relapses (22%).
Insights
Fosfomycin effectively treated osteomyelitis in 37 patients, achieving a 78% cure rate. This antibiotic showed promise for bone infection management, even in patients not undergoing surgery.
Area of Science:
- Infectious Diseases
- Orthopedic Surgery
- Pharmacology
Background:
- Osteomyelitis is a challenging bone infection requiring effective treatment strategies.
- Fosfomycin is a broad-spectrum antibiotic with potential utility in complex infections.
Purpose of the Study:
- To evaluate the efficacy of fosfomycin as a sole antibiotic treatment for osteomyelitis.
- To assess treatment outcomes in patients with osteomyelitis, including those who underwent surgery and those who did not.
Main Methods:
- A cohort of 37 osteomyelitis patients received fosfomycin treatment.
- Treatment involved parenteral and/or oral administration of fosfomycin at 4-8 g/day for approximately 3 weeks.
- Patients were categorized based on surgical intervention (sequestrectomy/fistulectomy) or conservative management.
Main Results:
- A definitive cure rate of 78% (29 out of 37 patients) was achieved.
- The study observed a 22% failure or relapse rate (8 out of 37 patients).
- Outcomes were assessed after one or two treatment courses.
Conclusions:
- Fosfomycin demonstrates significant efficacy as an antibiotic treatment for osteomyelitis.
- The antibiotic is effective in both surgically treated and non-surgically managed osteomyelitis patients.
- Fosfomycin offers a viable therapeutic option for managing bone infections.